\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[ngerman,greek,english]{babel}



\usepackage{float}








\begin{document}

\title{Mortality and associated factors in patients with COVID-19:
cross-sectional study}



\author[1]{Vergílio Carvalho}%
\author[2]{João Paulo Pontes}%
\author[2]{Demócrito Neto}%
\author[2]{Celso Borges}%
\author[2]{Gisele Campos}%
\author[3]{Hugo Leonardo Ribeiro}%
\author[1]{Waldemar do Amaral}%
\affil[1]{UFG}%
\affil[2]{Hospital Santa Genoveva}%
\affil[3]{Irmandade da Santa Casa de Misericordia de Sao Paulo}%


\vspace{-1em}



  
  \date{May 17, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
The novel virus severe acute respiratory syndrome coronavirus 2
(SARS-COV-2) is highly virulent and causes coronavirus disease 2019
(COVID-19), resulting in high morbidity and mortality mainly associated
with pulmonary complications. Because this virus is highly
transmissible, it was quickly spread globally, resulting in COVID-19
being declared as a pandemic. This study aimed to analyze the prevalence
of mortality and factors related to mortality due to COVID-19 in
patients with severe acute respiratory syndrome (SARS) at a university
hospital in the Central-West region of Brazil. This retrospective
cross-sectional study was based on an analysis of the medical records of
patients with SARS aged \textgreater{}18 years and admitted to an
intensive care unit due to COVID-19 with the requirement of invasive
mechanical ventilation. Hospital death was considered as an outcome
variable in this study. Moreover, demographic and lifestyle-related
variables as well as the therapeutic measures used during the hospital
stay were recorded and correlated with the death outcome. After
excluding 188 medical records, 397 were analyzed. Most participants were
men (59.7\%), and the mortality rate in patients with SARS due to COVID
19 was 46.1\%. Multiple regression analysis indicated that the
independent factors associated with mortality in patients with SARS due
to COVID 19 were the age of \textgreater{}60 years (p = 0.000) and use
of azithromycin (p = 0.012). The mortality rate in patients with SARS
due to COVID 19 and mortality was associated with older age and use of
azithromycin.%
\end{abstract}%



\sloppy


\textbf{Introduction}

The novel severe acute respiratory syndrome coronavirus~2 (SARS-CoV-2),
which causes the infection called coronavirus disease 2019 (COVID-19)
according to the World Health Organization, is one of the highly
virulent \selectlanguage{greek}β-\selectlanguage{english}coronaviruses that infects humans and causes acute
respiratory failure (ARF) due to pneumonia, with high mortality
rates\textsuperscript{1,2}. In addition, SARS-CoV-2 presents a major
challenge for healthcare systems across the world. This is mainly
because critically ill patients with ARF have to be monitored in an
intensive care unit (ICU) mainly under the support of invasive
mechanical ventilation (IMV) \textsuperscript{2--4}.

The diagnosis of COVID-19 is based on a reverse transcriptase polymerase
chain reaction test\textsuperscript{5}. To date, the treatment of
COVID-19 is undefined, and the therapies are aimed at controlling
clinical manifestations and providing ventilator support. Notably, some
drugs with therapeutic potential are emerging in the medical
field\textsuperscript{6}.

Although many researchers have investigated about
SARS-CoV-2,\textsuperscript{1--4} it is still important to explore the
factors associated with mortality in patients with COVID-19, including
the influence of sociodemographic conditions and the presence of chronic
diseases, lifestyle, and treatments. Therefore, this study aimed to
analyze the prevalence and factors related to mortality in patients with
severe acute respiratory syndrome (SARS) due to COVID-19 requiring IMV.
These data are important for adopting appropriate behavior in the
hospital environment.

\textbf{Methods}

This is a cross-sectional observational study conducted at an ICU in the
Central-West region of Brazil. The study was approved by the local
Research Ethics Committee on February 26, 2021 (protocol number:
4.563.056/2021; Certificate of Presentation for Ethical Appraisal (CAAE)
number: 43454621.2.0000.5077). Data collection was performed from March
12, 2021 to May 26, 2022.

Patients admitted to the ICU, diagnosed with SARS-CoV-2 infection,
requiring IMV, older than 18 years, and of both sexes, were included in
the study. Patients who had three or more incompletely analyzed
variables in their medical records, who had no record of death outcome
due to transfer to another institution, or who demonstrated unclear
association between deaths and SARS-CoV-2 infection were excluded from
the study.

Patients who had clinical dyspnea and required supplemental oxygen, and
the ratio of partial arterial pressure of oxygen (PaO\textsubscript{2})
and fraction of inspired oxygen (FiO\textsubscript{2})~[?]~300 mmHg were
considered as having ARF\textsuperscript{7}.

Data regarding sociodemographic characteristics, chronic diseases,
lifestyle, treatment, and hospital death were collected from medical
records. In-hospital death was considered an outcome or a dependent
variable. The considered sociodemographic variables were sex (male or
female) and age. The considered chronic disease variables were systemic
arterial hypertension; diabetes mellitus (DM); hypothyroidism;
hyperthyroidism; chronic obstructive pulmonary disease; cardiovascular
disease (CVD); cerebrovascular disease; mental health-related disease;
history of thrombosis; hepatitis A, B, and C; asthma; and liver failure.
The considered lifestyle variables were smoking, alcohol consumption,
and illicit drug use. The considered treatment variables were the use of
the prone position during hospitalization and the use of drugs, such as
dexamethasone, azithromycin, chloroquine, orhydroxychloroquine, and
low-molecular-weight heparin (enoxaparin).

For the sample size calculation, expected prevalence (or rate) of death
of 45\% was used,\textsuperscript{8} with an error margin of 5.0\% and a
95\% confidence interval (95\%~CI) for a population of 300,000
inhabitants residing in the city of Rio Verde, State of Goi\selectlanguage{ngerman}ás, Brazil,
and its neighboring districts. Thus, the sample size required for this
analysis (prevalence calculation) was found to be 380 patients.

All statistical analyses were performed using the Stata statistical
package, version 16.0 (StataCorp LLC, College Station, TX, USA). The
variables were presented as absolute numbers (n) and relative
frequencies (\%) with mean and standard deviation. Poisson's regression
was used to calculate the prevalence ratio and 95\%~CI, and\emph{p}
-values was obtained using the Wald test. Variables with a\emph{p}
-value of~\textless{}0.20 in bivariate analysis were included in
multiple hierarchical Poisson regression analyses, with robust variance
based on a hierarchical model\textsuperscript{9}. The independent
variables in this hierarchical analysis were classified as follows: (I)
demographic data (gender and age), (II) chronic diseases (DM and mental
illness), (III) clinical features (pronation), and (IV) medication use
(azithromycin and heparin). Statistical significance was established
using a cutoff value of \emph{p} ~\textless{}~0.05. Notably, the\emph{p}
-value of 0.000 indicates that the relationship is statistically
significant at the \selectlanguage{greek}α\selectlanguage{english}~=~0.05 level.

Variables without statistical power; that is, variables that after the
bivariate analysis presented n~\textless{}~10 in any stratum, were
excluded from the multiple regression analysis\textsuperscript{10}.
Additionally, the variables of hyperthyroidism, mental illness, asthma,
liver failure, smoking, and use of chloroquine/hydroxychloroquine were
excluded.

\textbf{Results}

Overall, 585 medical records were evaluated for eligibility in March
2021; of these, 188 were excluded (Fig.~1). Thus, 397 patients admitted
to the ICU with SARS due to COVID-19 and in need of IMV participated in
this study. Of these, 59.70\% were men with a mean age of 61.04~\selectlanguage{ngerman}±~0.76
years (range 20--111 years). Of the patients aged \textgreater{}60
years, 62.17\% were men and 37.83\% were women.

The prevalence of death in individuals with SARS due to COVID\selectlanguage{english}-19 was
46.10\% (63.93\% in men and 36.07\% in women). Data regarding the
prevalence and association of in-hospital death in patients with SARS
due to COVID\selectlanguage{english}-19 are presented in Table~1. The bivariate analysis
indicated that in-hospital death in patients with SARS due to COVID\selectlanguage{english}-19
was associated with the age of \textgreater{}60 years (prevalence ratio
{[}PR{]}~=~1.61; 95\%~CI: 1.26--2.04, \emph{p} ~=~0.000). In addition,
not having a diagnosis of hyperthyroidism (PR~=~0.46; 95\%~CI:
0.41--0.51, \emph{p} ~=~0.000), asthma (PR~=~0.46; 95\%~CI:
0.41--0.51,\emph{p} ~=~0.000), or liver failure (PR~=~0.46; 95\%~CI:
0.41--0.51,\emph{p} ~=~0.000) and not being a smoker (PR~=~0.61;
95\%~CI: 0.46--0.82, \emph{p} ~=~0.002) were considered protective
factors for mortality in individuals with SARS due to COVID\selectlanguage{english}-19.

Pronation at some point during hospitalization (PR~=~1.30; 95\%~CI:
1.03--1.64, \emph{p} ~=~0.028), use of azithromycin (RP~=~1.36; 95\%~CI:
1.09--1.69, \emph{p} ~=~0.005), and use of chloroquine or
hydroxychloroquine (PR~=~1.76; 95\%~CI: 1.121--2.77, \emph{p} ~=~0.014)
were associated with the mortality of patients hospitalized with SARS
due to COVID\selectlanguage{english}-19.

The variables included in the multiple regression analysis are shown in
Table~2. After the multiple regression analysis, the age of
\textgreater{}60 years (\emph{p} ~=~0.000) and use of azithromycin
(\emph{p} ~=~0.012) remained independently associated with the mortality
of patients with SARS due to COVID\selectlanguage{english}-19.

\textbf{Discussion}

The main results of the present study indicated a high prevalence of
death in individuals with SARS due to COVID\selectlanguage{english}-19 who required IMV. The
mortality rate was higher in individuals aged \textgreater{}60 years who
received azithromycin during SARS-CoV\selectlanguage{english}-2 infection.

The prevalence of death (46.1\%) in individuals hospitalized with SARS
due to COVID\selectlanguage{english}-19 was similar to that reported in other
studies\textsuperscript{2,8}. Notably, the patients included in the
present study were critically ill and treated with IMV on admission to
the ICU. These data are concerning and underscore that the high
mortality due to COVID-19 in critically ill patients may be because of
the continuous need for respiratory support and long stays in the
ICU\textsuperscript{2}.

The findings of the present study confirm that the survival of
critically ill patients with COVID-19 is particularly low in elderly
men. Moreover, age of \textgreater{}60 years was associated with
in-hospital death. A systematic review also stated that advanced age has
been recognized as an important risk factor for COVID\selectlanguage{english}-19
mortality\textsuperscript{11}. One explanation is that aging leads to
impaired functioning of multiple body systems, including the immune
system, which is a factor involved in the increased mortality due to
COVID-19 in the elderly\textsuperscript{11}.

Although mortality was higher in men, no statistical significance was
observed in the present study. Grasselli \emph{et al.} found a
relationship between the male sex and increased mortality in patients
with COVID\selectlanguage{english}-19 admitted to ICUs\textsuperscript{2}. In addition to higher
mortality, another large study involving 3.1 millions of patients with
COVID-19 reported that the male sex was associated with a higher ICU
admission rate\textsuperscript{12}. This phenomenon is attributed to the
fact that women have a higher number of CD4+ T cells, a more robust
cytotoxic activity of CD8+ T cells, and greater production of
immunoglobulin by B cells than men, enabling them to produce a more
efficient cellular and humoral response\textsuperscript{12}.

The use of azithromycin was also associated with in-hospital death.
Azithromycin is an antibiotic with anti-inflammatory and antiviral
properties, and it was thought to have activity against
SARS-CoV\selectlanguage{english}-2\textsuperscript{13}. However, based on different studies, a
systematic review reported that azithromycin, along with other
medications, including angiotensin-converting enzyme inhibitors,
aspirin, colchicine, hydroxychloroquine, inhaled corticosteroids,
intranasal corticosteroids, interferon beta, ivermectin,
lopinavir-ritonavir, and vitamin~C, has no important benefit on any
important outcome for patients with COVID\selectlanguage{english}-19\textsuperscript{14}. Based
on the present study design, this association between azithromycin and
death does not indicate causality.

Dexamethasone may be beneficial in patients with COVID\selectlanguage{english}-19, mainly in
more severe forms with exacerbated inflammatory activity, because of its
potential anti-inflammatory effect, which confers it the ability to
decrease gene transcription of several proinflammatory cytokines,
chemokines, and adhesion molecules by inhibiting the generation and
release of these mediators. However, dexamethasone may also prevent
B\selectlanguage{english}-cell-mediated antibody production and reduce T\selectlanguage{english}-cell immune function,
which may result in a higher plasma viral load and an increased risk of
secondary infections\textsuperscript{15}. Although the present study did
not report an association of dexamethasone use with mortality, a
randomized clinical trial in patients hospitalized with COVID\selectlanguage{english}-19 in the
United Kingdom comparing the use of 6~mg dexamethasone once daily for 10
days to placebo reported reduced 28-day mortality rate in patients with
COVID-19 receiving either IMV or oxygen therapy without IMV, with no
impact on mild cases without respiratory support\textsuperscript{16}.

Based on the current evidence, low-dose systemic steroids may be
considered for specific patients with COVID-19 who are critically ill or
require supplemental oxygen. However, routine use of corticosteroids
should be avoided, particularly in patients with mild symptoms or in the
early stages of the disease unless indicated for another reason, such as
those related to an individual's condition\textsuperscript{17,18}. The
retrospective nature of this study and lack of standardization of dose
and duration of therapy may have contributed to the absence of any
association of corticosteroid use with mortality in the present study.
This is because any use of dexamethasone, whether during the ICU stay or
earlier, was considered in this study.

The prone position contributes positively to the ventilation-perfusion
ratio and to the recruitment of dependent lung segments, culminating in
the opening of collapsed dependent alveoli and thereby providing better
gas exchange and oxygenation. Among mechanically ventilated non-COVID-19
patients with severe acute respiratory distress syndrome, those who were
ventilated in the prone position had a lower mortality
rate.\textsuperscript{19} The prone position can reduce the relative
fraction of the pulmonary shunt by 30\% compared with the supine group
in patients with injured lungs\textsuperscript{20}. A recent
meta-analysis demonstrated that the prone position improved the
PaO\selectlanguage{english}2/FiO2 \selectlanguage{english}ratio, with better SpO2 \selectlanguage{english}than the supine position, in patients
with COVID-19\textsuperscript{21}. Despite the aforementioned beneficial
effects, the present study found an association between pronation and
death, which may actually reflect the greater severity in patients who
were pronated to improve ventilation and gas exchange. However, after
the multiple regression analysis, pronation was not confirmed as an
independent factor associated with mortality.

The limitations of this study include the observational cross-sectional
design, which made it impossible to establish a causal relationship
between the variables. In addition, the data collection considered a
sample from a medium-sized city in the State of Goi\selectlanguage{ngerman}ás; therefore,
generalization of the results to the rest of the Brazilian population
must be done with caution. Variables that included previous lung disease
had a low prevalence; therefore, it was impossible to establish an
association with the outcome variable or to associate the use of drugs,
such as chloroquine and hydroxychloroquine, with mortality. In addition,
variables, such as the length of hospital stay, ventilation parameters,
and laboratory tests, were not examined. The authors recommend examining
these variables in future studies.

\textbf{Conclusions}

The authors conclude that individuals with SARS due to COVID\selectlanguage{english}-19
requiring IMV have high mortality. In addition, an association of
mortality with an age of \textgreater{}60 years and the use of
azithromycin was observed.

\textbf{References}

\begin{enumerate}
\tightlist
\item
  Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani
  Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019
  (COVID\selectlanguage{english}-19): mechanism of action, detection and recent therapeutic
  strategies. \emph{Virology} . 2020;551: 1-9. doi:
  10.1016/j.virol.2020.08.011
\item
  Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et
  al. Risk factors associated with mortality among patients with
  COVID\selectlanguage{english}-19 in intensive care units in Lombardy, Italy. \emph{JAMA Intern
  Med} . 2020;180(10): 1345-1355. doi: 10.1001/jamainternmed.2020.3539
\item
  Grieco DL, Menga LS, Cesarano M, Rosa T, Spadaro S, Bitondo MM, et al.
  Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on
  days free of respiratory support in patients with COVID\selectlanguage{english}-19 and
  moderate to severe hypoxemic respiratory failure: the HENIVOT
  randomized clinical trial. \emph{JAMA} . 2021;325(17): 1731-1743. doi:
  10.1001/jama.2021.4682
\item
  Shang Y, Pan C, Yang X, Zhong M, Shang X, Wu Z, et al. Management of
  critically ill patients with COVID\selectlanguage{english}-19 in ICU: statement from frontline
  intensive care experts in Wuhan, China. \emph{Ann Intensive Care} .
  2020;10(1): 73. doi: 10.1186/s13613-020-00689-1
\item
  Amawi H, Abu Deiab GI, AA. AA, Dua K, Tambuwala MM. COVID\selectlanguage{english}-19 pandemic:
  an overview of epidemiology, pathogenesis, diagnostics and potential
  vaccines and therapeutics. \emph{Ther Deliv} . 2020;11(4): 245-268.
\item
  Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al.
  Asymptomatic carrier state, acute respiratory disease, and pneumonia
  due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV\selectlanguage{english}-2):
  facts and myths. \emph{J Microbiol Immunol Infect} . 2020;53(3):
  404-412. doi: 10.1016/j.jmii.2020.02.012
\item
  Fauci AS, Longo DL, Hauser SL, et al. Harrison Medicina Interna. Rio
  de Janeiro: McGrawHill, 2019; 20a Edicao, v.2.
\item
  Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A,
  et al. Case fatality rates for patients with COVID\selectlanguage{english}-19 requiring
  invasive mechanical ventilation. A meta-analysis.~\emph{Am J Respir
  Crit Care Med} . 2021;203(1): 54-66. doi: 10.1164/rccm.202006-2405OC
\item
  Greenland S, Daniel R, Pearce N. Outcome modelling strategies in
  epidemiology: traditional methods and basic alternatives. \emph{Int J
  Epidemiol} . 2016;45(2): 565-575. doi: 10.1093/ije/dyw040
\item
  Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation
  study of the number of events per variable in logistic regression
  analysis. \emph{J Clin Epidemiol} . 1996;49(12): 1373-1379. doi:
  10.1016/s0895-4356(96)00236-3
\item
  Damayanthi HDWT, Prabani KIP, Weerasekara I. Factors associated for
  mortality of older people with COVID 19: A systematic review and
  meta-analysis. \emph{Gerontol Geriatr Med} . 2021;7:
  23337214211057392. doi: 10.1177/23337214211057392
\item
  Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C,
  Wedderburn LR, et al. Male sex identified by global COVID\selectlanguage{english}-19
  meta-analysis as a risk factor for death and ITU admission. \emph{Nat
  Commun} . 2020;11(1): 6317. doi: 10.1038/s41467-020-19741-6
\item
  Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al.
  Effect of oral azithromycin vs placebo on COVID\selectlanguage{english}-19 symptoms in
  outpatients with SARS-CoV\selectlanguage{english}-2 infection: A randomized clinical
  trial.\emph{JAMA} . 2021;326(6): 490-498. doi: 10.1001/jama.2021.11517
\item
  Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for
  COVID\selectlanguage{english}-19: living systematic review and network meta-analysis. Br J
  Clin Pharmacol. 2020;370: m2980.
\item
  Theoharides TC, Conti P. Dexamethasone for COVID\selectlanguage{english}-19? Not so
  fast.\emph{J Biol Regul Homeost Agents} . 2020;34(3): 1241-1243. doi:
  10.23812/20-EDITORIAL\_1-5
\item
  RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M,
  Bell JL, et al. Dexamethasone in hospitalized patients with
  COVID\selectlanguage{english}-19.\emph{N Engl J Med} . 2021;384(8): 693-704. doi:
  10.1056/NEJMoa2021436
\item
  Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D,
  Migkou M, Tzanninis IG. et al. Emerging treatment strategies for
  COVID\selectlanguage{english}-19 infection. \emph{Clin Exp Med} . 2021;21(2): 167-179. doi:
  10.1007/s10238-020-00671-y
\item
  Naime A, Bacha H, Tanni S. Uso de esteroides no tratamento da
  COVID\selectlanguage{english}-19. Projeto diretrizes. \emph{Associacao Medica Brasileira} .
  2021.
\item
  Guerin C, Reignier J, Richard JC. et al. Prone positioning in severe
  acute respiratory distress syndrome. N Engl J Med. 2013;6;368(23):
  2159-2168. doi: 10.1056/NEJMoa1214103
\item
  Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V.
  et al. Effect of prone positioning on the survival of patients with
  acute respiratory failure. \emph{N Engl J Med} . 2001;345(8): 568-573.
  doi: 10.1056/NEJMoa010043
\item
  Funakoshi K, Morita T, Kumanogoh A. Longer prehospitalization and
  preintubation periods in intubated non-survivors and ECMO patients
  with COVID\selectlanguage{english}-19: A systematic review and meta-analysis. \emph{Front Med
  (Lausanne} ). 2021;8: 727101. doi: 10.3389/fmed.2021.727101
\end{enumerate}

\textbf{Figure 1.} Study conduction flowchart according to the
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines.

\textbf{Table 1.} Association between hospital death in patients with
severe acute respiratory syndrome owing to COVID-19 and sociodemographic
data, chronic diseases, lifestyle, and treatment (n = 397).\selectlanguage{english}
\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright\strut
\textbf{Hospital death}\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright\strut
\textbf{Hospital death}\strut
\end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.19\columnwidth}\raggedright\strut
\textbf{Variable}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright\strut
\textbf{Frequency} \textbf{n (\%)}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright\strut
\textbf{Prevalence n (\%)}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright\strut
\textbf{PR (CI 95\%)}\strut
\end{minipage} & \begin{minipage}[t]{0.19\columnwidth}\raggedright\strut
p\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Genre\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0.119\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Male\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
237(59,70)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
117(63.93)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1.20(0.95-1.50)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Feminine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
160(40,30)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
66(36.07)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Age\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0.000}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
20-59\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
167(42,07)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
57(31.15)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
60 or more\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
230(57,93)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
126(68.85)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1.61(1.26-2.04)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Systemic arterial hypertension\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0.228\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
184(46.46)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
91(49.45)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
212(53.54)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
92(43.40)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1.139(0.85-1.52)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Diabetes mellitus\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0.082\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
275(69,27)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
64(34.97)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
122(30,73)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
119(65.03)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1.21(0.98-1.50)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Hypothyroidism\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0.800\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
374(94,21)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
173(94,54)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,06(0,66-1,72)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
23(5,79)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
10(5,46)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Hyperthyroidism\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0,000}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
396(99,75)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
182(99,45)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,46(0,41-0,51)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1(0,25)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1(0,55)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Chronic obstructive pulmonary disease\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,622\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
363(91,44)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
166(90,71)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,91(0,64-1,30)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
34(8,56)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
17(9,29)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Cardiovascular disease\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,546\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
356(89,67)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
166(90,71)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,12(0,77-1,64)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
41(10,33)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
17(9,29)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Cerebrovascular disease\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,595\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
377(94,96)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
175(95,63)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,16(0,67-2,00)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
20(5,04)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
8(4,37)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Mental health related illness\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,185\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
384(96,73)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
175(95,63)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,74(0,47-1,15)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
13(3,27)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
8(4,37)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Thrombosis history\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
-\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
N\selectlanguage{ngerman}ão\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
396(99,75)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
183(100,00)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
-\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Sim\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1(0,25)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0(0,00)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
-\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Hepatitis A\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,469\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
392(98,74)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
180(98,36)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,31(0,63- 2,69)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
5(1,26)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
3(1,64)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Hepatitis B\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,469\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
392(98,74\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
180(98,36)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,31(0,63-2,70)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
5(1,26)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
3(1,64)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Hepatitis C\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,469\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
392(98,74)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
180(98,36)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,31(0,63-2,70)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
5(1,26)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
3(1,64)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Asthma\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0,000}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
391(98,49)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
179(97,81)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,46(0,41-0,51)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (treating)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1(0,25)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1(0,55)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (cured)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
5(1,26)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
3(1,64)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,59(0,29-1,23)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Liver failure\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0,000}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
390(98,24)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
178(97,27)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,46(0,41-0,51)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (treating)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1(0,25)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1(0,55)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (cured)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
6(1,51)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
4(2,19)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,66(0,38-1,17)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Smoking\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0,002}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
369(92,95)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
167(91,26)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,61(0,46-0,82)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (smoker)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
9(2,27)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
2(1,09)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,30(0,09-1,06)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (already smoked)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
19(4,79)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
14(7,65)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Alcohol consumption\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,397\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
345(86,90)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
162(88,52)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,16(0,82-1,65)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
52(13,10)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
21(11,48)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Use of illicit drugs\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,294\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
388(97,73)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
177(96,72)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
,68(0,30-1,53)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (user)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
3(0,76)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
2(1,09)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes (already used)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
6(1,51)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
4(2,19)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,67(0,30-1,48)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Pronation\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0,028}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
154(38,99)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
60(32,97)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
241(61,01)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
122(67,03)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,30(1,03-1,64)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Dexamethasone use\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,861\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
No\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
79(19,95)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
37(20,33)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Yes\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
317(80,05)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
145(79,67)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,98(0,75-1,27)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Use of Azithromycin\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0,005}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
N\selectlanguage{ngerman}ão\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
207(52,41)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
81(44,75)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Sim\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
188(47,59)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
100(55,25)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,36(1,09-1,69)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Use of chloroquine or hydroxychloroquine\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\textbf{0,014}\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
N\selectlanguage{ngerman}ão\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
390(98,73)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
117(97,79)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,57(0,36-0,89)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Sim\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
5(1,27)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
4(2,21)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Use of Heparin (Enoxaparin)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
0,074\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
N\selectlanguage{ngerman}ão\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
68(17,17)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
24(13,19)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
Sim\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
328(82,83)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
158(86,81)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
1,36(0,97-1,92)\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
CI: confidence interval; PR: adjusted prevalence ratio. The Wald test
was used to calculate all ``p'' values, p \textless{} 0.05 was
considered statistically significant (\textbf{bold}). Variables with p
\textless{} 0.20 were later analyzed by multiple hierarchical Poisson
regression.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
CI: confidence interval; PR: adjusted prevalence ratio. The Wald test
was used to calculate all ``p'' values, p \textless{} 0.05 was
considered statistically significant (\textbf{bold}). Variables with p
\textless{} 0.20 were later analyzed by multiple hierarchical Poisson
regression.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
CI: confidence interval; PR: adjusted prevalence ratio. The Wald test
was used to calculate all ``p'' values, p \textless{} 0.05 was
considered statistically significant (\textbf{bold}). Variables with p
\textless{} 0.20 were later analyzed by multiple hierarchical Poisson
regression.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
CI: confidence interval; PR: adjusted prevalence ratio. The Wald test
was used to calculate all ``p'' values, p \textless{} 0.05 was
considered statistically significant (\textbf{bold}). Variables with p
\textless{} 0.20 were later analyzed by multiple hierarchical Poisson
regression.\strut
\end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright\strut
CI: confidence interval; PR: adjusted prevalence ratio. The Wald test
was used to calculate all ``p'' values, p \textless{} 0.05 was
considered statistically significant (\textbf{bold}). Variables with p
\textless{} 0.20 were later analyzed by multiple hierarchical Poisson
regression.\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

\textbf{Table 2} . Multiple regression analysis of the association of
in-hospital death and sociodemographic data, chronic diseases, and
treatment in patients with severe acute respiratory syndrome due to
COVID-19 (n = 397).\selectlanguage{english}
\begin{longtable}[]{@{}lll@{}}
\toprule
& \textbf{Hospital death} & \textbf{Hospital death}\tabularnewline
\midrule
\endhead
\textbf{Variable} & \textbf{PR (CI 95\%)} & p\tabularnewline
Genre & & 0,053\tabularnewline
Male & 1 &\tabularnewline
Feminine & 0,80(0,64-1,00) &\tabularnewline
Age & & \textbf{0,000}\tabularnewline
20-59 & 1 &\tabularnewline
60 or more & 1,55(1,22-1,97) &\tabularnewline
Diabetes mellitus & & 0,252\tabularnewline
No & 1 &\tabularnewline
Yes & 1,13(0,92-1,39) &\tabularnewline
Pronation & & 0,237\tabularnewline
No & 1 &\tabularnewline
Yes & 1,15(0,91-1,45) &\tabularnewline
Use of Azithromycin & & \textbf{0,012}\tabularnewline
No & 1 &\tabularnewline
Yes & 1,32(1,06-1,64) &\tabularnewline
Use of Heparin (Enoxaparin) & & 0,057\tabularnewline
No & 1 &\tabularnewline
Yes & 1,40(0,99-1,97) &\tabularnewline
CI: confidence interval; PR: prevalence ratio. Wald's test was used to
calculate all p-values. p \textless{} 0.05 was considered statistically
significant (\textbf{bold}). & CI: confidence interval; PR: prevalence
ratio. Wald's test was used to calculate all p-values. p \textless{}
0.05 was considered statistically significant (\textbf{bold}). & CI:
confidence interval; PR: prevalence ratio. Wald's test was used to
calculate all p-values. p \textless{} 0.05 was considered statistically
significant (\textbf{bold}).\tabularnewline
\bottomrule
\end{longtable}

\textbf{Hosted file}

\verb`Title_page.docx`  available at \url{https://authorea.com/users/526522/articles/596300-mortality-and-associated-factors-in-patients-with-covid-19-cross-sectional-study}

\textbf{Hosted file}

\verb`Figure 1.docx`  available at \url{https://authorea.com/users/526522/articles/596300-mortality-and-associated-factors-in-patients-with-covid-19-cross-sectional-study}

\textbf{Hosted file}

\verb`Table 1.docx`  available at \url{https://authorea.com/users/526522/articles/596300-mortality-and-associated-factors-in-patients-with-covid-19-cross-sectional-study}

\textbf{Hosted file}

\verb`Table 2.docx`  available at \url{https://authorea.com/users/526522/articles/596300-mortality-and-associated-factors-in-patients-with-covid-19-cross-sectional-study}

\selectlanguage{english}
\FloatBarrier
\end{document}

